Accretion / Dilution Math Under Pressure

Interviewers love accretion/dilution because the math isn't hard but candidates have memorized one scenario and freeze the moment an input shifts.

Pure stock at 25x acquiring at 15x? They've seen that question forty times. Throw in 30% cash, 70% stock, after-tax synergies of $80M, transaction fees, and a step-up in basis on the seller's PP&E, and the same candidate who recited the shortcut perfectly thirty seconds ago is staring at the ceiling. The shortcut isn't the answer. The shortcut is one corner of a four-dimensional equation, and the interviewer's job is to move you to a corner you didn't prep.

This piece walks the full mechanic at a level where you can rebuild the math on the fly when inputs change. Then it works through Bristol-Myers Squibb's 2019 acquisition of Celgene, a deal that was publicly disclosed as more than 40% accretive in year one, and unpacks how that number actually got built.

The Principle in One Sentence

A deal is accretive when the seller's earnings yield exceeds the weighted cost of acquisition. Dilutive when it doesn't. Everything else is a special case.

Most candidates carry three or four disconnected shortcuts in their head — one for stock deals, one for cash, one for debt — and don't realize they're all the same equation viewed from different angles. Anchor on the principle. The shortcuts become trivial. The pressure questions become solvable.

#### 100% Stock Deals: The Classic Shortcut

For a pure stock deal, the buyer is "paying" with its own equity, which costs the buyer its own earnings yield. The deal is accretive when the seller's earnings yield is higher than the buyer's.

Or equivalently: accretive when buyer's P/E is higher than seller's purchase P/E.

Worked example. Buyer trades at 25x earnings, acquires seller at a purchase multiple of 15x. Buyer's earnings yield is 4%, seller's is 6.7%. The buyer issues stock costing 4% to acquire earnings worth 6.7%. Accretive.

The mechanic underneath: new shares issued = purchase equity value divided by buyer's share price. Combined EPS = (Buyer net income + Seller net income) divided by (Buyer shares + new shares). The yield comparison is just a shorthand for that calculation.

#### Cash Deals: Foregone Interest

For a pure cash deal, no new shares are issued. The "cost" is the after-tax interest the buyer was earning on the cash, now foregone.

Cost of cash acquisition = Interest rate on cash × (1 − tax rate)

In the current rate environment, cash sitting in money-market instruments earns roughly 4% pre-tax, or about 3% after-tax at a 25% effective rate. Most acquisitions at 15–20x P/E carry earnings yields of 5–6.7%, which clears the after-tax cost of cash easily. That's why cash-rich balance sheets create deal pressure even when the strategic logic is thin — the math is hard to make dilutive when your cost of capital is 3%.

The mechanic: combined net income drops by the after-tax foregone interest. Share count stays the same. EPS goes up.

#### Debt Deals: After-Tax Cost of Debt

Same principle, different cost line.

Cost of debt acquisition = Interest rate on new debt × (1 − tax rate)

Investment-grade debt at 5–6% pre-tax becomes roughly 4–4.5% after-tax at a 25% rate. Seller yield needs to clear that for the deal to be accretive on debt alone.

In a rising rate environment, debt-financed deals become harder to make accretive, which is why M&A volume tracks the credit cycle so tightly. When rates were near zero from 2020 to early 2022, almost any acquisition at any multiple was accretive on debt because the after-tax cost of debt was 2% or lower. As rates climbed, the math tightened and deal flow contracted.

#### Mixed Deals: Weighted Cost of Acquisition

This is the piece where candidates lock up under pressure, and it's the simplest of the four once you see the structure. The cost of acquisition for a mixed deal is just the weighted average of the component costs.

WCA = (% Cash × After-tax cash cost)
+ (% Debt × After-tax debt cost)
+ (% Stock × Buyer's earnings yield)

Worked example. Buyer trades at 20x (5% yield). Seller is acquired at 15x (6.7% yield). Deal funded 30% cash (3% after-tax), 30% debt (4.5% after-tax), 40% stock (5% yield).

WCA = (0.30 × 3.0%) + (0.30 × 4.5%) + (0.40 × 5.0%)
= 0.90% + 1.35% + 2.00%
= 4.25%

Seller yield 6.7% minus WCA 4.25% equals roughly 245 basis points of net accretion before synergies. Plug numbers in. The output is the answer to "by how much."

The reason this question kills candidates isn't the formula. It's that interviewers will hand you the inputs in any order and expect you to assemble the WCA on the fly. "Buyer at 18x, seller at 22x, funded 40% cash, 20% debt, 40% stock, debt rate 6%, cash rate 4%, both at a 25% tax rate. Accretive or dilutive?" Most candidates need ninety seconds with a pen. Good candidates can call the direction in fifteen seconds and the magnitude in thirty.

#### The Full Math: Combined EPS

When interviewers want the actual EPS calculation, not the shortcut:

Combined NI = Buyer NI
+ Seller NI
− After-tax foregone interest on cash
− After-tax interest on new debt
+ After-tax synergies
− After-tax incremental D&A from PP&E step-up

Combined shares = Buyer shares + new shares from stock issuance
Combined EPS = Combined NI / Combined shares
Accretion % = (Combined EPS − Buyer EPS) / Buyer EPS

Every line earns its place. Foregone interest on cash and interest on new debt show up as reductions to combined net income, taxed at the buyer's rate because they're operating-line items. Synergies, almost always cost synergies in base case modeling, flow in after tax. Incremental D&A from writing up the seller's PP&E to fair value reduces NI in early years until the write-up is fully depreciated. Combined shares include only the new shares issued for the stock portion of the deal, not phantom shares for the cash portion.

This is the calculation an interviewer can ask you to walk through line by line. Memorize the structure. Plug numbers as they come.

A Worked Example: Bristol-Myers Squibb / Celgene

On January 3, 2019, Bristol-Myers Squibb announced the acquisition of Celgene for approximately $74 billion in equity value. The deal closed in November 2019. It's one of the cleanest real-world demonstrations of how a high-premium acquisition can still throw off enormous accretion, because almost every mechanic from the sections above shows up at once.

The structure. Each Celgene share received 1.0 BMS share, $50.00 in cash, and one tradeable Contingent Value Right (CVR) tied to three FDA approval milestones. The CVR would pay $9 if the FDA approved three of Celgene's late-stage drugs by March 31, 2021. Based on BMS's closing price of $52.43 on January 2, 2019, the cash and stock consideration was worth $102.43 per Celgene share — split almost exactly fifty-fifty between cash ($50) and stock ($52.43), with the CVR as a separate contingent piece.

The accretion claim. BMS disclosed that the combination was expected to be more than 40 percent accretive to standalone EPS in the first full year following close. That's an enormous headline number — large enough that it became the central pitch of the deal to BMS shareholders.

Where the 40% came from. Three drivers stack:

First, the cash portion. Roughly half the deal was funded with cash, which BMS raised by issuing approximately $33 billion of investment-grade debt. After-tax cost of that debt was in the 3–4% range. Celgene's earnings yield at the acquisition multiple was substantially higher: Celgene's 2018 non-GAAP EPS was around $7 against a per-share consideration of $102, an earnings yield of roughly 7%. The spread between Celgene's earnings yield and the after-tax cost of debt was 300–400 basis points, and that spread compounds across the cash half of the deal.

Second, the stock portion. BMS traded at a lower forward P/E than Celgene was being acquired at, which by the 100% stock shortcut would push toward dilution on that piece. But the stock portion was only half the deal, and the cash spread more than offset it.

Third — the wildcard — synergies. BMS guided to approximately $2.5 billion of run-rate cost synergies to be achieved by 2022. After tax at a 21% federal rate, that's roughly $2 billion of additional combined net income at full run-rate. Layered onto a standalone BMS net income of roughly $6.5 billion, the synergies alone represent something like 30% of pre-deal earnings. They don't fully ramp in year one, but even partial realization in the first twelve months adds materially to accretion.

The yield-vs-cost spread gets you most of the way to the 40%. Cost synergies do the rest. That's how a deal at a 53% premium to Celgene's pre-announcement share price still throws off accretion at scale.

Synergies: The Wildcard That Breaks the Shortcut

The simple yield-comparison shortcut breaks the moment synergies enter the calculation. Cost synergies (facility consolidation, redundant headcount, vendor consolidation, duplicate corporate functions) get added to combined NI on an after-tax basis. They tilt the math toward accretion regardless of what the buyer paid, because they're independent of price.

Bankers separate hard synergies (cost) from soft (revenue). Hard synergies are line items with names attached, like "consolidate Newark facility, $40M annual savings," and bankers underwrite them with high confidence. Soft synergies (cross-selling, channel expansion, pricing power) are almost always discounted by 50% or more in base case modeling, and frequently excluded entirely. Sell-side bankers will include aggressive revenue synergy estimates in pitch decks. Buy-side bankers and investment committees treat them as optional upside, not base case.

The synergy multiple concept matters for the strategic question. Present value of after-tax synergies versus premium paid. If PV of synergies exceeds the premium, the deal is — at least on synergy economics — value-creating beyond what the seller's standalone earnings provided. If synergies don't cover the premium, the buyer is transferring value to the seller's shareholders and trying to make it up on the integration. BMS guided to roughly $20 billion in PV of synergies on a $74 billion deal. That's a reasonable cover for the premium they paid. Whether it actually played out that way is a separate question — synergy realization in pharma M&A is contested terrain.

Why EPS Accretion Doesn't Mean Value Creation

The contrarian point that earns associate-level credit.

EPS accretion is visible. Boards talk about it, sell-side analysts model it, press releases lead with it. That visibility is exactly why it's a flawed metric. You can buy a structurally declining business at a stupid premium and still get accretion if you fund it cheaply enough — the accretion comes from the spread between funding cost and earnings yield, not from the strategic logic of owning the asset. Conversely, a strategically brilliant acquisition can be dilutive in year one if the multiple is high enough and the synergy ramp is slow.

The right metric for value creation is whether the deal creates equity value: premium paid versus the present value of synergies plus strategic value plus terminal value uplift. Accretion is the political number. Value creation is the math.

BMS/Celgene is a useful case study for this exact tension. The deal was massively accretive on announcement. It also attracted public opposition from Starboard Value LP, which delivered an open letter to BMS stockholders arguing the deal was ill-advised. The critique wasn't that the math was wrong. The critique was that BMS was buying Celgene's near-term earnings, concentrated in a few drugs facing patent cliffs, at a premium that the long-term franchise value couldn't support. Accretive, but allegedly value-destroying. Five years on, the verdict is mixed and depends on which BMS shareholder you ask.

What MDs Push On, When This Terrain Comes Up

"Is this accretion sustainable or one-time?"

"What's the implied synergy multiple?"

"How much premium would make this dilutive?"

"What if synergies miss by 50%?"

What Interviewers Push On

Concrete pressure points and the right responses.

"50/50 cash and stock at 12x with $100 million after-tax synergies, defend it."

"What if the synergies are pre-tax, not after-tax?"

"Is 1% accretion meaningful?"

"What's the breakeven premium?"

"How do transaction fees affect accretion?"

"What about goodwill amortization?"

The 90-Second Walkthrough

A sample compressed walkthrough that hits the structure without getting lost in mechanics:

"A deal is accretive when the seller's earnings yield is higher than the buyer's weighted cost of acquisition. For 100% stock, that simplifies to buyer's P/E being higher than seller's purchase P/E. For 100% cash, it simplifies to seller's yield exceeding the after-tax foregone interest. For mixed deals, you take a weighted average of each funding source against the seller's yield.

The actual EPS math is combined NI (buyer plus seller, less after-tax interest costs from cash and debt, plus after-tax synergies, less incremental D&A from any PP&E step-up) divided by combined shares, which is buyer shares plus new shares issued for the stock portion.

Synergies are the wildcard. A high-premium deal can still be massively accretive if the cost synergies are large enough — BMS/Celgene was 40%+ accretive in year one at a 53% premium because the cash funding cost was low and cost synergies were $2.5 billion run-rate.

The important meta-point: accretion isn't the same as value creation. A deal can be accretive and still destroy value, or dilutive in year one and create enormous value long-term. The IC's job is to look past the headline accretion to the synergy multiple and the durability of the combined earnings stream."

Roughly 110 seconds spoken at a measured pace. Hits the principle, runs the special cases, flags synergies as the wildcard, lands on the strategic critique. That's the version that sounds like an analyst who's actually built one.

---

Where to Drill

The Analyst-level interviewer on HARDO is built for the kind of input-shifting that accretion/dilution questions live in: "now run it with 60% cash instead of 30%," "what if the debt rate moves 200 basis points," "synergies came in at half the guide." The Associate-level interviewer pushes on the strategic layer: "defend the synergy assumption," "what premium would make this dilutive," "is BMS/Celgene a good deal." If the math is the part of your prep stack that still freezes when inputs shift, those are the seats to take.